VEGF165 ELISA Kit (Vascular Endothelial Growth Factor165)
INTENDED USE
Human VEGF165 ELISA kit can measure concentrations of vascular endothelial growth factor165 (VEGF165) present is plasma, serum, biological fluids or tissue homogenate samples.
INTRODUCTION
VEGF165 is a splice variant of vascular endothelial growth factor A (VEGF-A) that potently stimulates angiogenesis. Along with VEGF121, it represents one of the most abundant and biologically active isoforms among those generated by alternative exon splicing of the VEGF-A pre-mRNA. Though shorter than VEGF189 and 206 variants, the presence of exon 7 encoded sequences equips VEGF165 with optimal abilities to activate VEGF receptor 2 (VEGFR2) as well as bind extracellular matrix components to establish chemotactic gradients guiding endothelial cell migration.
Through these dual features, VEGF165 serves as a multifaceted regulator of angiogenesis—the growth of new blood vessels from preexisting vasculature. Its receptor-mediated signaling induces endothelial cells to proliferate, migrate, and invade to form new vascular structures. This requires stringent spatiotemporal control over VEGF165 bioavailability, which extracellular matrix binding helps achieve. Heparan sulfate proteoglycans retain VEGF165 in the matrix following its directional deposition and surface immobilization by cysteine-rich domains. Subsequent proteolytic liberation then establishes haptotactic gradients guiding vascular sprouting based on matrix-sequestered cues.
Besides driving healthy angiogenesis in wound healing and development, dysregulation of VEGF165 critically underlies pathological neovascularization in cancer, atherosclerosis, eye disorders, and inflammatory conditions. Its overexpression via hypoxia-inducible factor-1 stimulates tumor angiogenesis enabling growth and metastasis. Meanwhile, insufficient VEGF impairs reparative vascularization in cardiac disease. Hence appropriately tuning context-specific VEGF165 signaling remains an active area of therapeutic investigation using biologics, gene therapy, and small molecules targeting production, interaction with matrix and receptors, or downstream signaling.
CONTENT
All reagents supplied need to be stored at 2 °C – 8 °C, unopened reagents will retain reactivity until expiration date. Do not use reagents beyond this date.
- One 96-Well Plate: Pre-coated with anti-VEGF165 antibody.
- Standards: Lyophilized recombinant.
- Sample/Standard Dilution Buffer.
- Biotinylated-labelled Antibody.
- Antibody Dilution Buffer.
- HRP-Streptavidin Conjugate (SABC).
- SABC Dilution Buffer.
- TMB Substrate.
- Wash Buffer (25x).
- Plate Sealer.
- Product Instructions.
TYPICAL RESULTS
For this VEGF165 ELISA kit, it is recommended that a standard curve is generated for each assay carried out.
Standard Curve: 0, 31.25, 62.5, 125, 250, 500, 1000, 2000 pg/ml.
Reactivity: Human
Sensitivity: 18.75 pg/ml
Range: 31.25 – 2000 pg/ml
Principle: Sandwich, Double Antibody
Application: Research Use Only.
ASSAY CHARACTERISTICS
– Specificity: Highly specific for VEGF165, no cross reactivity or interference between VEGF165 and analogues was detected.
– Recovery: Serum (91 – 101%), EDTA Plasma (89 – 103%), Heparin Plasma (92 – 98%).
– Linearity: Serum (85 – 104%), EDTA Plasma (83 – 98%), Heparin Plasma (81 – 93%).
– Precison Intra-Assay: CV < 8%
– Precison Inter-Assay: CV < 10%
REFERENCES
- VEGF165-induced vascular permeability requires NRP1 for ABL-mediated SRC family kinase activation. J Exp Med. (2017) 214 (4): 1049-1064. Fantin A., et al.
- Release kinetics of VEGF165 from a collagen matrix and structural matrix changes in a circulation model. Head Face Med. (2010) 6: 17. Kleinheinz J., et al.
ADDITIONAL INFORMATION
- Full Name: VEGF165 ELISA Kit (Vascular Endothelial Growth Factor165)
- Reactivity: Human
- Sample Type: Plasma, Tissue Homogenates, Serum, Biological Fluids
- Sensitivity: 18.75 pg/ml
OTHER RELATED ELISA KITS
Online Enquiry Form
"*" indicates required fields
